A61P 25 - Drugs for disorders of the nervous system

Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2011
10/06/2011	US20110245264 Modulators of G Protein-Coupled Receptor 88
10/06/2011	US20110245263 2-heteroaryl-pyrrolo[3,4-c]pyrrole derivatives and their use as scd
10/06/2011	US20110245262 Compounds for treating proliferative disorders
10/06/2011	US20110245257 Heterocyclic compounds and their uses
10/06/2011	US20110245251 Modulators of the prostacyclin (pgi2) receptor useful for the treatment of disorders related thereto
10/06/2011	US20110245250 Potassium ion channel modulators & uses thereof
10/06/2011	US20110245248 Isoquinoline derivatives
10/06/2011	US20110245247 Novel small molecule potentiators of metabotropic glutamate receptors
10/06/2011	US20110245245 Methods of treatment comprising the administration of heteroaryl compounds
10/06/2011	US20110245240 Cgrp receptor antagonists
10/06/2011	US20110245237 Aryl-cyclohexyl-tetraazabenzo[e]azulenes
10/06/2011	US20110245232 Novel small molecule potentiators of metabotropic glutamate receptors i
10/06/2011	US20110245231 Active substance and pharmaceutical composition for treating alcohol dependence, and a method for obtaining and the use of said active substance
10/06/2011	US20110245230 Pyrimidyl cyclopentanes as akt protein kinase inhibitors
10/06/2011	US20110245227 Pyridone gpr119 g protein-coupled receptor agonists
10/06/2011	US20110245225 Quinazolinamide derivatives
10/06/2011	US20110245223 Heterocyclic compounds
10/06/2011	US20110245222 Methods for Using Carboxamide, Sulfonamide and Amine Compounds
10/06/2011	US20110245221 Aryl isoxazole compounds with antitumoural activities
10/06/2011	US20110245214 Organic compounds
10/06/2011	US20110245209 Pyridopyrimidine derivatives and methods of use thereof
10/06/2011	US20110245208 Compositions and methods for the treatment of somatosensory disorders
10/06/2011	US20110245204 Cycloalkane-containing sphingosine 1-phosphate agonists
10/06/2011	US20110245188 Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
10/06/2011	US20110245180 Modified Peptide that reduces pain in peripheral neuropathy
10/06/2011	US20110245172 Biocompatible oligomer-polymer compositions
10/06/2011	US20110245169 Protection, restoration and enhancement of erythropoietin responsive cells, tissues and organs
10/06/2011	US20110245159 Salts, Solvates and Pharmaceutical Compositions of Macrocyclic Ghrelin Receptor Agonists and Methods of Using the Same
10/06/2011	US20110245158 High Protein Supplement
10/06/2011	US20110244564 Cystine knot molecules
10/06/2011	US20110244064 composition for the treatment of hypertension
10/06/2011	US20110244059 Inhibiting obesity progression by inhibiting adipocyte differentiation with a pre-adipocyte autophagy inhibitor
10/06/2011	US20110244057 Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological conditions
10/06/2011	US20110244042 Stabilized formulations of cns compounds
10/06/2011	US20110244022 Transdermal delivery patch
10/06/2011	US20110244020 Drug condensation aerosols and kits
10/06/2011	US20110243985 Self-adhesive matrix system comprising a styrene block copolymer
10/06/2011	US20110243975 Transformed soybean plant which accumulates vaccine, and use thereof
10/06/2011	US20110243962 Therapeutic use of specific ligand in msrv associated diseases
10/06/2011	US20110243959 Modulating neuronal plasticity and treatment of neuronal loss by modulationg wnt7a or wnt7b modulation
10/06/2011	US20110243957 Materials and methods for preventing or treating neurodegenerative conditions associated with abeta peptide accumulation
10/06/2011	US20110243945 Anti-Inflammatory Agents
10/06/2011	US20110243943 Treatment using relaxin-fusion proteins with extended in vivo half-lives
10/06/2011	US20110243940 Bicyclic pyranone derivatives and methods of use thereof
10/06/2011	US20110243938 Methods to Reduce B-Helper T Cells to Treat Autoimmune Diseases
10/06/2011	US20110243936 TNFalpha-NEUTRALIZING ANTIBODIES
10/06/2011	US20110243926 Anti-p-selectin antibodies and methods of using the same to treat inflammatory diseases
10/06/2011	US20110243924 Novel methods
10/06/2011	US20110243917 Composition for the prevention and treatment of absence seizures comprising pkc agonist as an effective ingredient
10/06/2011	US20110243895 Generation of patient-specific differentiated cell types by epigenetic induction
10/06/2011	US20110243893 Markers for determination of patient responsiveness
10/06/2011	US20110243890 Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells With a Virus
10/06/2011	US20110243889 Opioid and opioid-like compounds and uses thereof
10/06/2011	US20110243881 Biocompatible polymers, process for their preparation and compositions containing them
10/06/2011	US20110243879 Methods of treating hepatic encephalopathy
10/06/2011	US20110243842 Mammalian receptor proteins; related reagents and methods
10/06/2011	DE102011006425A1 Pharmaceutical composition, useful for treating and/or preventing e.g. Parkinson's disease, dementia, neuropathic pain, retinitis pigmentosa, multiple sclerosis and amyotrophic lateral sclerosis, comprises flupirtine and N-acetylcysteine
10/06/2011	DE102010013587A1 N-(Aminoacyl)-Amino-Ester N- (aminoacyl) -amino-ester
10/06/2011	CA2795158A1 Abuse-deterrent transdermal formulations of opiate agonists and agonist-antagonists
10/06/2011	CA2795156A1 Transdermally deliverable opioid prodrugs, abuse-resistant compositions and methods of using opioid prodrugs
10/06/2011	CA2795080A1 Purine compounds
10/06/2011	CA2795062A1 Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
10/06/2011	CA2795023A1 Crystal forms of o-desmethylvenlafaxine fumarate
10/06/2011	CA2795009A1 Aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists
10/06/2011	CA2795006A1 Purine compounds used as cb2 agonists
10/06/2011	CA2794734A1 Transdermal delivery patch
10/06/2011	CA2794620A1 Use of the phytocannabinoid cannabidivarin (cbdv) in the treatment of epilepsy
10/06/2011	CA2793692A1 Methods for treating parkinson's disease and other disorders of dopaminergic neurons of the brain
10/06/2011	CA2793612A1 Dimethyl sulfoxide (dmso) formulations for treating autism
10/06/2011	CA2793580A1 Composition comprising the amyloid beta 1-6 peptide coupled to a virus-like particle and an adjuvant
10/06/2011	CA2793313A1 Novel nk-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in nk-3 receptors mediated disorders
10/05/2011	EP2371959A2 Treatment of neurodegenerative disease through intracranial delivery of siRNA
10/05/2011	EP2371954A1 Compositions and methods for short interfering nucleic acid inhibition of NAv1.8
10/05/2011	EP2371861A1 Monoclonal antibodies against extracellular loops of C5aR
10/05/2011	EP2371838A1 Novel immunogenic compositions for the prevention and treatment of meningococcal disease
10/05/2011	EP2371837A1 Novel immunogenic compositions for the prevention and treatment of meningococcal disease
10/05/2011	EP2371836A1 Novel immunogenic compositions for the prevention and treatment of meningococcal disease
10/05/2011	EP2371818A1 Hydroxybenzoate salts of metanicotine compounds
10/05/2011	EP2371814A1 Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
10/05/2011	EP2371421A1 Ligands of insulin degrading enzyme and their uses
10/05/2011	EP2371420A1 Veterinary pharmaceutical compositions for the treatment of pain and inflammation
10/05/2011	EP2371379A2 New formulation for increasing bioavailability of neurturin
10/05/2011	EP2371367A1 Method of treating men with testosterone supplement and 5alpha reductase inhibitor
10/05/2011	EP2371366A1 Heterocyclo inhibitors of potassium channel function
10/05/2011	EP2371340A1 Instrument for alleviating addictive drug craving, method for using same and method for treating addictive drug dependence
10/05/2011	EP2370439A1 Lactams as beta secretase inhibitors
10/05/2011	EP2370436A1 Azaquinolinone derivatives and uses thereof
10/05/2011	EP2370431A1 1, 2, 4 -oxadiazole derivatives and their therapeutic use
10/05/2011	EP2370427A1 N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and uses thereof
10/05/2011	EP2370426A1 N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl]methyl}-2-heteroarylamine derivatives and uses thereof
10/05/2011	EP2370405A1 Triple reuptake inhibitors and methods of their use
10/05/2011	EP2370089A1 Compounds and methods for the treatment of autoimmune and inflammatory disease
10/05/2011	EP2370075A1 Use of geranyl-geranyl transferase in treating spinal cord lesions
10/05/2011	EP2370071A1 Novel oxime derivatives of 3,5-seco-4-nor-cholestane, pharmaceutical compositions containing same, and method for preparing same
10/05/2011	EP2370058A1 Liposomal composition for convection-enhanced delivery to the central nervous centre
10/05/2011	EP2240492B1 Process for the preparation of asenapine and intermediate products used in said process
10/05/2011	EP2144506B1 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
10/05/2011	EP2129377B1 Liquid formulations of salts of 4-[2-(4-methylphenylsulfanyl)phenyl]piperidine
10/05/2011	EP1874311B1 A method for preventing, delaying or reverting abnormal amyloid deposition
10/05/2011	EP1858520B1 Quinazolinone t-type calcium channel antagonists

1 ... 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 ... 1833